Interpretation of the evidence for the efficacy and safety of statin therapy

Few cardiovascular questions are as settled in the evidence and as unsettled in the public mind as the safety of statins. This landmark review, from the trialists who ran many of the defining studies, was written to close that gap.

Synthesizing randomized data on tens of thousands of patients, the authors put numbers to both sides of the ledger. Benefit: each 1 mmol/L reduction in LDL cholesterol cuts major vascular events by roughly a quarter per year of treatment, in both primary and secondary prevention. Harm: serious side effects are rare and usually reversible, and — the central claim — the muscle aches so often blamed on statins occur at nearly the same rate on placebo, the signature of a nocebo effect rather than a drug effect.

The practical takeaway is blunt: prescribe statins confidently to patients who qualify, and meet side-effect fears with the evidence that most reported symptoms aren’t caused by the drug. The status-quo resistance here is unusual in that it comes from the anti-treatment direction — statin skeptics, alternative-medicine advocates, and media coverage that amplified the very side-effect narrative the review sets out to correct.

We rate the evidence high — a comprehensive synthesis of randomized trials by the field’s leading trialists, the strongest tier of evidence available. The fair caveat, transparently disclosed, is that several authors built their careers on these trials, which critics read as a conflict. Its clinical significance is equally high: statin underuse driven by misinformation causes preventable heart attacks and strokes, and this paper is among the most authoritative correctives available.